<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39375326</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Structural basis for receptor-binding domain mobility of the spike in SARS-CoV-2 BA.2.86 and JN.1.</ArticleTitle><Pagination><StartPage>8574</StartPage><MedlinePgn>8574</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">8574</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-024-52808-2</ELocationID><Abstract><AbstractText>Since 2019, SARS-CoV-2 has undergone mutations, resulting in pandemic and epidemic waves. The SARS-CoV-2 spike protein, crucial for cellular entry, binds to the ACE2 receptor exclusively when its receptor-binding domain (RBD) adopts the up-conformation. However, whether ACE2 also interacts with the RBD in the down-conformation to facilitate the conformational shift to RBD-up remains unclear. Herein, we present the structures of the BA.2.86 and the JN.1 spike proteins bound to ACE2. Notably, we successfully observed the ACE2-bound down-RBD, indicating an intermediate structure before the RBD-up conformation. The wider and mobile angle of RBDs in the up-state provides space for ACE2 to interact with the down-RBD, facilitating the transition to the RBD-up state. The K356T, but not N354-linked glycan, contributes to both of infectivity and neutralizing-antibody evasion in BA.2.86. These structural insights the spike-protein dynamics would help understand the mechanisms underlying SARS-CoV-2 infection and its neutralization.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yajima</LastName><ForeName>Hisano</ForeName><Initials>H</Initials><Identifier Source="ORCID">0009-0000-0065-4125</Identifier><AffiliationInfo><Affiliation>Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anraku</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5731-0902</Identifier><AffiliationInfo><Affiliation>Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaku</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Kanako Terakado</ForeName><Initials>KT</Initials><Identifier Source="ORCID">0000-0003-4913-7502</Identifier><AffiliationInfo><Affiliation>Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plianchaisuk</LastName><ForeName>Arnon</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0004-2416-0508</Identifier><AffiliationInfo><Affiliation>Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okumura</LastName><ForeName>Kaho</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-9996-8913</Identifier><AffiliationInfo><Affiliation>Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Liberal Arts, Sophia University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakada-Nakura</LastName><ForeName>Yoshiko</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0598-796X</Identifier><AffiliationInfo><Affiliation>Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atarashi</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases; Shinjuku-ku, Tokyo, 162-8640, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hemmi</LastName><ForeName>Takuya</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9782-9696</Identifier><AffiliationInfo><Affiliation>Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuroda</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-2390-4785</Identifier><AffiliationInfo><Affiliation>Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases; Shinjuku-ku, Tokyo, 162-8640, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Yoshimasa</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-6342-4087</Identifier><AffiliationInfo><Affiliation>Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases; Shinjuku-ku, Tokyo, 162-8640, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kita</LastName><ForeName>Shunsuke</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3969-302X</Identifier><AffiliationInfo><Affiliation>Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasaki</LastName><ForeName>Jiei</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5129-2336</Identifier><AffiliationInfo><Affiliation>Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sumita</LastName><ForeName>Hiromi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0009-0003-8114-0100</Identifier><AffiliationInfo><Affiliation>Research Administration Office, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Genotype to Phenotype Japan (G2P-Japan) Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Jumpei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maenaka</LastName><ForeName>Katsumi</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-5459-521X</Identifier><AffiliationInfo><Affiliation>Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pathogen Structure, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Station for Biosurfaces and Drug Discovery, Hokkaido University, Sapporo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Kei</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-4431-1380</Identifier><AffiliationInfo><Affiliation>Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. keisato@g.ecc.u-tokyo.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. keisato@g.ecc.u-tokyo.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. keisato@g.ecc.u-tokyo.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan. keisato@g.ecc.u-tokyo.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CREST, Japan Science and Technology Agency, Kawaguchi, Japan. keisato@g.ecc.u-tokyo.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. keisato@g.ecc.u-tokyo.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Collaboration Unit for Infection, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan. keisato@g.ecc.u-tokyo.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC-University of Glasgow Centre for Virus Research, Glasgow, UK. keisato@g.ecc.u-tokyo.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashiguchi</LastName><ForeName>Takao</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7578-7571</Identifier><AffiliationInfo><Affiliation>Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan. hashiguchi.takao.1a@kyoto-u.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CREST, Japan Science and Technology Agency, Kawaguchi, Japan. hashiguchi.takao.1a@kyoto-u.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kyoto University Immunomonitoring Center, Kyoto University, Kyoto, Japan. hashiguchi.takao.1a@kyoto-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JP223fa627009</GrantID><Agency>Japan Agency for Medical Research and Development (AMED)</Agency><Country /></Grant><Grant><GrantID>JP24jf0126002</GrantID><Agency>Japan Agency for Medical Research and Development (AMED)</Agency><Country /></Grant><Grant><GrantID>JP20ae0101047</GrantID><Agency>Japan Agency for Medical Research and Development (AMED)</Agency><Country /></Grant><Grant><GrantID>JPJSCCA20240006</GrantID><Agency>MEXT | Japan Society for the Promotion of Science (JSPS)</Agency><Country /></Grant><Grant><GrantID>JPMJCR20H8</GrantID><Agency>MEXT | JST | Core Research for Evolutional Science and Technology (CREST)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="Y">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="Y">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="Y">Protein Domains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Matsuno</LastName><ForeName>Keita</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nao</LastName><ForeName>Naganori</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sawa</LastName><ForeName>Hirofumi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mizuma</LastName><ForeName>Keita</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Jingshu</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kida</LastName><ForeName>Izumi</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mimura</LastName><ForeName>Yume</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ohari</LastName><ForeName>Yuma</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Shinya</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsuda</LastName><ForeName>Masumi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Lei</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oda</LastName><ForeName>Yoshikata</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferdous</LastName><ForeName>Zannatul</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shishido</LastName><ForeName>Kenji</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohri</LastName><ForeName>Hiromi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iida</LastName><ForeName>Miki</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fukuhara</LastName><ForeName>Takasuke</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tamura</LastName><ForeName>Tomokazu</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Rigel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Saori</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsujino</LastName><ForeName>Shuhei</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ito</LastName><ForeName>Hayato</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Misawa</LastName><ForeName>Naoko</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guo</LastName><ForeName>Ziyi</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hinay</LastName><ForeName>Alfredo A</ForeName><Initials>AA</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Usui</LastName><ForeName>Kaoru</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saikruang</LastName><ForeName>Wilaiporn</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lytras</LastName><ForeName>Spyridon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uriu</LastName><ForeName>Keiya</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoshimura</LastName><ForeName>Ryo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawakubo</LastName><ForeName>Shusuke</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nishumura</LastName><ForeName>Luca</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kosugi</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fujita</LastName><ForeName>Shigeru</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>M Tolentino</LastName><ForeName>Jarel Elgin</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Luo</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pan</LastName><ForeName>Lin</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Wenye</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yo</LastName><ForeName>Maximilian Stanley</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horinaka</LastName><ForeName>Kio</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suganami</LastName><ForeName>Mai</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiba</LastName><ForeName>Mika</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yasuda</LastName><ForeName>Kyoko</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iida</LastName><ForeName>Keiko</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strange</LastName><ForeName>Adam Patrick</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ohsumi</LastName><ForeName>Naomi</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Shiho</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogawa</LastName><ForeName>Eiko</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fukuda</LastName><ForeName>Tsuki</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Osujo</LastName><ForeName>Rina</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoshimura</LastName><ForeName>Kazuhisa</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadamas</LastName><ForeName>Kenji</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagashima</LastName><ForeName>Mami</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asakura</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Isao</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakagawa</LastName><ForeName>So</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takayama</LastName><ForeName>Kazuo</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Rina</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deguchi</LastName><ForeName>Sayaka</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Yukio</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakata</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Futatsusako</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sakamoto</LastName><ForeName>Ayaka</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yasuhara</LastName><ForeName>Naoko</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Tateki</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakajima</LastName><ForeName>Yukari</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Irie</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawabata</LastName><ForeName>Ryoko</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sasaki-Tabata</LastName><ForeName>Kaori</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikeda</LastName><ForeName>Terumasa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nasser</LastName><ForeName>Hesham</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Ryo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Begum</LastName><ForeName>M S T Monira</ForeName><Initials>MSTM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jonathan</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mugita</LastName><ForeName>Yuka</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leong</LastName><ForeName>Sharee</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Otowa</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ueno</LastName><ForeName>Takamasa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Motozono</LastName><ForeName>Chihiro</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toyoda</LastName><ForeName>Mako</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saito</LastName><ForeName>Akatsuki</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kosaka</LastName><ForeName>Anon</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawano</LastName><ForeName>Miki</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matsubara</LastName><ForeName>Natsumi</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nishiuchi</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zahradnik</LastName><ForeName>Jiri</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrikopoulos</LastName><ForeName>Prokopios</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Padilla-Blanco</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Konar</LastName><ForeName>Aditi</ForeName><Initials>A</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>23</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39375326</ArticleId><ArticleId IdType="pmc">PMC11458767</ArticleId><ArticleId IdType="doi">10.1038/s41467-024-52808-2</ArticleId><ArticleId IdType="pii">10.1038/s41467-024-52808-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO. BA.2.86 Initial Risk Evaluation, 21 November, 2023.) (2023).</Citation></Reference><Reference><Citation>Kaku, Y. et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. Lancet Infect. Dis.24, e82 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38184005</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, S. et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect. Dis.24, e70–e72 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38109919</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura, T. et al. Virological characteristics of the SARS-CoV-2 BA.2.86 variant. Cell Host Microbe32, 170–180.e112 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38280382</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, X. et al. Immune escape of BA.2.86 is comparable to XBB subvariants from the plasma of BA.5- and BA.5-XBB-convalescent subpopulations. J. Med Virol.96, e29417 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38258345</ArticleId></ArticleIdList></Reference><Reference><Citation>Willett, B. J. et al. Omicron BA.2.86 cross-neutralising activity in community sera from the UK. Lancet402, 2075–2076 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37952549</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu, P. et al. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 omicron BA.2.86 and FLip variants. Cell.187, 585–595.e6 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10872432</ArticleId><ArticleId IdType="pubmed">38194968</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan, K. et al. Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant. Nat. Commun.14, 8078 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10700484</ArticleId><ArticleId IdType="pubmed">38057313</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, W. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature426, 450–454 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095016</ArticleId><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantuti-Castelvetri, L. et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science370, 856–860 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857391</ArticleId><ArticleId IdType="pubmed">33082293</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly, J. L. et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science370, 861–865 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7612957</ArticleId><ArticleId IdType="pubmed">33082294</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen, J. et al. TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry. Cell186, 3427–3442.e3422 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10409496</ArticleId><ArticleId IdType="pubmed">37421949</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamming, I. et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol.203, 631–637 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7167720</ArticleId><ArticleId IdType="pubmed">15141377</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell181, 271–280.e278 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmann, H. et al. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc. Natl. Acad. Sci. USA102, 7988–7993 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1142358</ArticleId><ArticleId IdType="pubmed">15897467</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science367, 1260–1263 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164637</ArticleId><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai, Y. et al. Distinct conformational states of SARS-CoV-2 spike protein. Science369, 1586–1592 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7464562</ArticleId><ArticleId IdType="pubmed">32694201</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito, A. et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant. Cell Host Microbe30, 1540–1555.e1515 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9578327</ArticleId><ArticleId IdType="pubmed">36272413</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura, T. et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat. Commun.14, 2800 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10187524</ArticleId><ArticleId IdType="pubmed">37193706</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura, T. et al. Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant. Nat. Commun.15, 1176 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10853506</ArticleId><ArticleId IdType="pubmed">38332154</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, B. A. et al. Furin cleavage site is key to SARS-CoV-2 pathogenesis. Nature591, 293–299 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8175039</ArticleId><ArticleId IdType="pubmed">33494095</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson, C. B., Farzan, M., Chen, B. &amp; Choe, H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol.23, 3–20 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsujino, S. et al. Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant. Microbiol Immunol. 68, 305–330 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38961765</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalls, V. et al. Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike. Cell Rep.39, 111009 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9174147</ArticleId><ArticleId IdType="pubmed">35732171</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature608, 593–602 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385493</ArticleId><ArticleId IdType="pubmed">35714668</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai, Y. et al. Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants. Science373, 642–648 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9245151</ArticleId><ArticleId IdType="pubmed">34168070</ArticleId></ArticleIdList></Reference><Reference><Citation>Saville, J. W. et al. Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants. Nat. Commun.13, 742 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8826856</ArticleId><ArticleId IdType="pubmed">35136050</ArticleId></ArticleIdList></Reference><Reference><Citation>Punjani, A. &amp; Fleet, D. J. 3DFlex: determining structure and motion of flexible proteins from cryo-EM. Nat. Methods20, 860–870 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10250194</ArticleId><ArticleId IdType="pubmed">37169929</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannar, D. et al. Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding. Cell Rep.37, 110156 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8642162</ArticleId><ArticleId IdType="pubmed">34914928</ArticleId></ArticleIdList></Reference><Reference><Citation>Philip, A. M., Ahmed, W. S. &amp; Biswas, K. H. Reversal of the unique Q493R mutation increases the affinity of Omicron S1-RBD for ACE2. Comput Struct. Biotechnol. J.21, 1966–1977 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10006685</ArticleId><ArticleId IdType="pubmed">36936816</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, L. et al. SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency. Cell187, 596–608.e517 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11317634</ArticleId><ArticleId IdType="pubmed">38194966</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, Y. et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature614, 521–529 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9931576</ArticleId><ArticleId IdType="pubmed">36535326</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Q. et al. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature624, 639–644 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37871613</ArticleId></ArticleIdList></Reference><Reference><Citation>Bdeir, N. et al. Reverse mutational scanning of spike BA.2.86 identifies the epitopes contributing to immune escape from polyclonal sera. Preprint at medRxiv, 10.1101/2024.01.03.23300575 (2024).</Citation></Reference><Reference><Citation>Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature588, 682–687 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092461</ArticleId><ArticleId IdType="pubmed">33045718</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, Z. et al. Omicron SARS-CoV-2 mutations stabilize spike up-RBD conformation and lead to a non-RBM-binding monoclonal antibody escape. Nat. Commun.13, 4958 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9399999</ArticleId><ArticleId IdType="pubmed">36002453</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, Y. et al. Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.2 variant compared to BA.1 and their possible mouse origins. Cell Res. 32, 609–620 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9152305</ArticleId><ArticleId IdType="pubmed">35641567</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, L. et al. Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1. Cell185, 2952–2960.e2910 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212699</ArticleId><ArticleId IdType="pubmed">35809570</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Y. et al. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat. Rev. Immunol.23, 189–199 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9514166</ArticleId><ArticleId IdType="pubmed">36168054</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, W., Gui, M., Wang, X. &amp; Xiang, Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog.14, e1007236 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6107290</ArticleId><ArticleId IdType="pubmed">30102747</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki, R. et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature603, 700–705 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942852</ArticleId><ArticleId IdType="pubmed">35104835</ArticleId></ArticleIdList></Reference><Reference><Citation>Uriu, K. et al. Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant. Lancet Infect. Dis.23, e460–e461 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37734391</ArticleId></ArticleIdList></Reference><Reference><Citation>Khare, S. et al. GISAID’s Role in Pandemic Response. China CDC Wkly3, 1049–1051 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8668406</ArticleId><ArticleId IdType="pubmed">34934514</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksamentov, I., Roemer, C., Hodcroft, E. B. &amp; Neher, R. A. Nextclade: clade assignment, mutation calling and quality control for viral genomes. J. Open Source Softw.6, 3773 (2021).</Citation></Reference><Reference><Citation>Moshiri, N. ViralMSA: massively scalable reference-guided multiple sequence alignment of viral genomes. Bioinformatics37, 714–716 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32814953</ArticleId></ArticleIdList></Reference><Reference><Citation>Capella-Gutiérrez, S., Silla-Martínez, J. M. &amp; Gabaldón, T. trimAl: a tool for automated alignment trimming in large-scale phylogenetic analyses. Bioinformatics25, 1972–1973 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2712344</ArticleId><ArticleId IdType="pubmed">19505945</ArticleId></ArticleIdList></Reference><Reference><Citation>Minh, B. Q. et al. IQ-TREE 2: New models and efficient methods for phylogenetic inference in the genomic era. Mol. Biol. Evol.37, 1530–1534 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7182206</ArticleId><ArticleId IdType="pubmed">32011700</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalyaanamoorthy, S., Minh, B. Q., Wong, T. K. F., von Haeseler, A. &amp; Jermiin, L. S. ModelFinder: Fast model selection for accurate phylogenetic estimates. Nat. Methods14, 587–589 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5453245</ArticleId><ArticleId IdType="pubmed">28481363</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang, D. T., Chernomor, O., von Haeseler, A., Minh, B. Q. &amp; Vinh, L. S. UFBoot2: Improving the ultrafast bootstrap approximation. Mol. Biol. Evol.35, 518–522 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5850222</ArticleId><ArticleId IdType="pubmed">29077904</ArticleId></ArticleIdList></Reference><Reference><Citation>Millard, S. P. An R Package for Environmental Statistics. (Springer, New York, 2013).</Citation></Reference><Reference><Citation>Yu, G. Using ggtree to visualize data on tree-like structures. Curr. Protoc. Bioinforma.69, e96 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32162851</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashiguchi, T. et al. Structure of the measles virus hemagglutinin bound to its cellular receptor SLAM. Nat. Struct. Mol. Biol.18, 135–141 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21217702</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science369, 1501–1505 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402631</ArticleId><ArticleId IdType="pubmed">32703906</ArticleId></ArticleIdList></Reference><Reference><Citation>Punjani, A., Rubinstein, J. L., Fleet, D. J. &amp; Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods14, 290–296 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28165473</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardone, G., Heymann, J. B. &amp; Steven, A. C. One number does not fit all: mapping local variations in resolution in cryo-EM reconstructions. J. Struct. Biol.184, 226–236 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3837392</ArticleId><ArticleId IdType="pubmed">23954653</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen, E. F. et al. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput Chem.25, 1605–1612 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Goddard, T. D. et al. UCSF ChimeraX: Meeting modern challenges in visualization and analysis. Protein Sci.27, 14–25 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5734306</ArticleId><ArticleId IdType="pubmed">28710774</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley, P., Lohkamp, B., Scott, W. G. &amp; Cowtan, K. Features and development of Coot. Acta Crystallogr D. Biol. Crystallogr66, 486–501 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr D. Struct. Biol.75, 861–877 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778852</ArticleId><ArticleId IdType="pubmed">31588918</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams, C. J. et al. MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci.27, 293–315 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5734394</ArticleId><ArticleId IdType="pubmed">29067766</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider, C., Raybould, M. I. J. &amp; Deane, C. M. SAbDab in the age of biotherapeutics: Updates including SAbDab-nano, the nanobody structure tracker. Nucleic Acids Res. 50, D1368–d1372 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8728266</ArticleId><ArticleId IdType="pubmed">34986602</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunbar, J. et al. SAbDab: the structural antibody database. Nucleic Acids Res. 42, D1140–D1146 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965125</ArticleId><ArticleId IdType="pubmed">24214988</ArticleId></ArticleIdList></Reference><Reference><Citation>Leman, J. K. et al. Macromolecular modeling and design in Rosetta: recent methods and frameworks. Nat. Methods17, 665–680 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7603796</ArticleId><ArticleId IdType="pubmed">32483333</ArticleId></ArticleIdList></Reference><Reference><Citation>Eswar, N. et al. Comparative protein structure modeling using Modeller. Curr. Protoc. Bioinforma. Chapter5, 6 (2006). Unit-5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4186674</ArticleId><ArticleId IdType="pubmed">18428767</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence, M. C. &amp; Colman, P. M. Shape complementarity at protein/protein interfaces. J. Mol. Biol.234, 946–950 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8263940</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku, Y. et al. Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5. Lancet Infect. Dis.23, e395–e396 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37708910</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosugi, Y. et al. Characteristics of the SARS-CoV-2 omicron HK.3 variant harbouring the FLip substitution. Lancet Microbe.5, e313 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38219759</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa, H., Yamamura, K. &amp; Miyazaki, J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 108, 193–199 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1660837</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira, I. et al. SARS-CoV-2 B.1.617 mutations L452R and E484Q are not synergistic for antibody evasion. J. Infect. Dis.224, 989–994 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8420622</ArticleId><ArticleId IdType="pubmed">34260717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozono, S. et al. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. Nat. Commun.12, 848 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7870668</ArticleId><ArticleId IdType="pubmed">33558493</ArticleId></ArticleIdList></Reference><Reference><Citation>Motozono, C. et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe29, 1124–1136.e1111 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8205251</ArticleId><ArticleId IdType="pubmed">34171266</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell185, 457–466.e454 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8733787</ArticleId><ArticleId IdType="pubmed">34995482</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>